Takeda Downgraded by Moody's on Lofty Debt After Shire Deal

Bookmark
(Bloomberg) -- Takeda Pharmaceutical Co.’s credit rating was cut by Moody’s Investors Service, which cited the drugmakers’ ballooning debt level following its $62 billion acquisition of Shire Plc.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.